Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study
Author(s):
Dougados, M.; Heijde, D. van der; Chen, Y.C.; Greenwald, M.; Drescher, E.; Liu, J.J.; Beattie, S.; Torre, I. de la; Rooney, T.; Schlichting, D.; Bono, S. de; Emery, P.; Bookman, A.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-06-30
Language
English
Is part of
Journal of Rheumatology (2016), Vol. 43, no. 6, p. 1188-1188
